tirzepatide cvot 💡 New insight in diabetes care: In patients with T2DM and ASCVD, the SURPASS-CVOT trial found that was noninferior to dulaglutide for major cardiovascular events (12.2% vs 13.1%; HR 0.92). What Tirzepatide demonstrates cardiovascular protection in

Employers must decide how to manage eligibility and avoid misuse

Always consult a qualified dermatologist before beginning the treatment and ensure that injections are administered in a sterile and professional environment

Re-titrating takes 8 to 20 weeks to reach a therapeutic maintenance dose but reduces the rate of early discontinuation due to adverse effects

They randomized 30 participants meeting their criteria to a semaglutide or placebo group, each receiving once weekly injections

GLP-1R expressed in the nucleus tractus solitarius signals to suppress appetite, delay gastric emptying and reduce body weight, and this is proposed to be mediated through PKA, decreasing phosphorylation of AMPK (22, 89, 110)